Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

elotuzumab

- PMLiVE

FDA knocks back J&J and Bayer’s Xarelto in ACS

Follows unanimous negative committee vote

- PMLiVE

FDA approves clinical trial wearables

Greenlights Camntech's MotionWatch and Pro-Diary medical devices

- PMLiVE

Merck cuts MK-3475 deals with Pfizer, Amgen and Incyte

Sees combination potential for cancer prospect

- PMLiVE

NIH forges $230m research alliance with pharma

Brings 10 pharma companies together to speed up research in Alzheimer’s, diabetes and arthritis

- PMLiVE

J&J sets new pharma standard for sharing clinical trial data

Chooses Yale to act as independent trial data request review body

- PMLiVE

Janssen announces new group to tackle global health

Will implement R&D and access strategies to support areas with unmet public health need

Bristol-Myers Squibb (BMS) building

BMS shares fall on nivolumab jitters despite solid Q4 results

Awaiting data from ongoing studies before advancing cancer prospect

J&J expected to make best use of digital in 2014

Company's strong approach to marketing strategy praised in Digital Futures 2014 survey

- PMLiVE

Amgen cholesterol antibody scores in another phase III trial

Evolocumab effective in patients who cannot take statins

- PMLiVE

J&J earnings leap on buoyant pharma sales

CEO Alex Gorsky praises "outstanding" pharmaceutical performance

- PMLiVE

AZ gets green light in EU for Xigduo diabetes combination

Wins approval for first line extension of Forxiga

- PMLiVE

Xarelto should not be approved in ACS says FDA panel

Advisory committee votes against new indication for Bayer and J&J’s anticoagulant

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links